

Factsheet Q1/2014



COMPANY PROFILE

Fresenius is a global health care group providing products and services for dialysis, hospitals and outpatient medical care. In addition, Fresenius focuses on hospital operations. We also manage projects and provide services for hospitals and other health care facilities. More than 200,000 employees have dedicated themselves to the service of health in about 100 countries worldwide.

FRESENIUS GROUP IN FIGURES

€ in millions	Q1/2014	Q1/2013	Change	2013
Sales and Earnings				
Sales	5,212	4,890	7%	20,331
EBIT ¹	643	696	-8%	3,045
Net income (before special items) ²	228	224	2%	1,051
Earnings per ord. share in € (before special items) ²	1.27	1.26	1%	5.88
Balance sheet and cash flow				
Total assets	34,284		5% ⁶	32,758
Non-current assets	25,628		3% ⁶	24,786
Equity ³	13,619		3% ⁶	13,260
Equity ratio ³	40%			41%
Net debt/EBITDA ⁴	3.2		--	2.5
Investments ⁵	1,158	258	--	3,827
Operating cash flow	140	444	-68%	2,320
Operating cash flow in % of sales	2.7%	9.1%	--	11.4%
Profitability				
EBIT margin ¹	12.3%	14.2%	--	15.0%
Return on equity after taxes (ROE) ²	12.5%		--	12.8%
Return on operating assets (ROOA) ¹	9.6%		--	10.6%
Return on invested capital (ROIC) ¹	7.8%		--	8.8%
Employees	201,924		13% ⁶	178,337

¹ 2014 before Fenwal integration costs (€1 million) and book gain from the divestment of two HELIOS hospitals (€22 million); 2013 before Fenwal integration costs

² Net income attributable to shareholders of Fresenius SE & Co. KGaA; 2014 before Fenwal integration costs (€1 million) and book gain from the divestment of two HELIOS hospitals (€21 million); 2013 before Fenwal integration costs


³ Including noncontrolling interest

⁴ Pro forma including acquired hospitals from Rhön-Klinikum AG; before Fenwal integration costs and book gain from the divestment of two HELIOS hospitals; 2013 pro forma excluding advances made for the acquisition of hospitals from Rhön-Klinikum AG; before Fenwal integration costs

⁵ Investments in property, plant and equipment and intangible assets, acquisitions


⁶ Change compared to December 31, 2013

SALES BY REGION



GROUP STRUCTURE

The operating business comprises the four business segments Fresenius Medical Care, Fresenius Kabi, Fresenius Helios and Fresenius Vamed, all of which are legally independent entities managed by the operating parent company Fresenius SE & Co. KGaA.



¹ As of March 31, 2013

BUSINESS SEGMENTS


€ in millions		Q1/2014	Change	FY/2013	Change
FRESENIUS MEDICAL CARE	Sales	2,602	-1%	11,000	2%
	EBIT	325	-13%	1,699	-6%
FRESENIUS KABI	Sales	1,213	-4%	4,996	10%
	EBIT	201 ¹	-15%	926 ¹	-1%
FRESENIUS HELIOS	Sales	1,227	46%	3,393	6%
	EBIT	114 ²	31%	390	21%
FRESENIUS VAMED	Sales	191	4%	1,020	21%
	EBIT	6	20%	55	8%

¹ Before Fenwal integration costs

² Before book gain from the divestment of two HELIOS hospitals

- ▶ **Fresenius Medical Care** is the world's leading provider of services and products for patients with chronic kidney failure. As of March 31, 2014, Fresenius Medical Care was treating 270,570 patients in 3,263 dialysis clinics.
- ▶ **Fresenius Kabi** offers infusion therapies, intravenously administered generic drugs and clinical nutrition for seriously and chronically ill patients in the hospital and outpatient environments. The company is also a leading supplier of medical devices and transfusion technology products.
- ▶ **Fresenius Helios** is Germany's largest hospital operator. HELIOS owns 109 hospitals, thereof 85 acute care clinics including six maximum care hospitals in Berlin-Buch, Duisburg, Erfurt, Krefeld, Schwerin and Wuppertal and 24 post-acute care clinics. HELIOS treats more than 4.2 million patients per year, thereof more than 1.2 million inpatients, and operates more than 33,000 beds.
- ▶ **Fresenius Vamed** manages projects and provides services for hospitals and other health care facilities worldwide.


SALES BY BUSINESS SEGMENT



FRESENIUS SHARE / ADR

	Share
Securities code no.	578 560
ISIN	DE0005785604
Ticker symbol	FRE
ADR CUSIP	35804M105
ADR Ticker symbol	FSNUY
Number of shares (March 31, 2014)	179,824,079
Market capitalization (March 31, 2014)	€20.4 billion

RELATIVE SHARE PRICE PERFORMANCE FRESENIUS SHARE VS. DAX



FRESENIUS GROUP'S SENIOR NOTES

Issuer	ISIN	Volume in million	Coupon	Maturity
Fresenius Finance B. V.	XS1013954646	€300	2.375%	2019
Fresenius Finance B. V.	XS0759200321	€500	4.25%	2019
Fresenius Finance B. V.	XS0873432511	€500	2.875%	2020
Fresenius Finance B. V.	XS1013955379	€450	3.00%	2021
Fresenius Finance B. V.	XS1026109204	€450	4.00%	2024
Fresenius US Finance II, Inc.	USU31436AD72	US\$500	9.00%	2015
Fresenius US Finance II, Inc.	XS0390398344	€275	8.75%	2015
Fresenius US Finance II, Inc.	USU31436AG04	US\$300	4.250%	2021
Convertible bonds				
Fresenius SE & Co. KGaA	DE000A1YC3T6	€500	0.00%	2019

Bonds of Fresenius Medical Care can be found under [www.fmc-ag.com/Credit Relations](http://www.fmc-ag.com/Credit_Relations).

SHARE PERFORMANCE¹

1 month	+0,9%
1 st quarter	+1,8%
1 year	+18,0%
5 years	+297,9%
10 years	+408,7%

¹ Effective date/closing price: March 31, 2014

GROUP FINANCIAL TARGETS 2014¹


	Targets 2014
Sales, growth (in constant currency)	12% – 15%
Net income ² , growth (in constant currency)	2% – 5%
Capital expenditure	~6% of sales

¹ Includes contributions from the acquisition of hospitals from Rhön-Klinikum AG

² Net income attributable to shareholders of Fresenius SE & Co. KGaA; 2014 before integration costs for Fenwal (€30-40 million) and the hospitals acquired from Rhön-Klinikum AG and net of book gain from the divestment of two HELIOS hospitals (€21 million); 2013 before Fenwal integration costs (€40 million)

For the outlook of the business segments please see the Investor News of May 6, 2014.

DEVELOPMENT SHARE DIVIDENDS IN €



¹ Proposal

This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.

Fresenius SE & Co. KGaA
Registered Office: Bad Homburg, Germany
Commercial Register: Amtsgericht Bad Homburg, HRB 11852
Chairman of the Supervisory Board: Dr. Gerd Krick

General Partner: Fresenius Management SE
Registered Office: Bad Homburg, Germany
Commercial Register: Amtsgericht Bad Homburg, HRB 11673
Management Board: Dr. Ulf M. Schneider (Chairman), Mats Henriksson, Dr. Francesco De Meo, Dr. Jürgen Götz, Rice Powell, Stephan Sturm, Dr. Ernst Wastler
Chairman of the Supervisory Board: Dr. Gerd Krick

FINANCIAL CALENDAR

	Dates
Annual General Meeting, Frankfurt/Main	May 16, 2014
Payment of dividend ¹	May 19, 2014
Report on 1 st half 2014	July 31, 2014
Report on 1 st –3 rd quarter 2014	November 4, 2014

Please note that these dates could be subject to modifications.

¹ Subject to prior approval by the Annual General Meeting

CONTACT

Fresenius SE & Co. KGaA

Else-Kröner-Straße 1, 61352 Bad Homburg v. d. H.
e-mail: ir-fre@fresenius.com
Internet: www.fresenius.com

Birgit Grund
Senior Vice President
Investor Relations

Telephone: ++49 61 72 6 08-24 85
Telefax: ++49 61 72 6 08-24 88

Leslie Iltgen
Vice President
Investor Relations

Telephone: ++49 61 72 6 08-44 78
Telefax: ++49 61 72 6 08-24 88